Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash from Financing Activities for 16 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1.4% to -$5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.6 million, a 17.11% increase, with the full-year FY2025 number at -$10.6 million, up 17.11% from a year prior.
  • Cash from Financing Activities was -$5.3 million for Q4 2025 at Anika Therapeutics, down from -$13000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $667000.0 in Q4 2022 to a low of -$7.0 million in Q3 2021.
  • A 5-year average of -$2.1 million and a median of -$986500.0 in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 1011.67% in 2022, then plummeted 10645.65% in 2023.
  • Anika Therapeutics' Cash from Financing Activities stood at $60000.0 in 2021, then skyrocketed by 1011.67% to $667000.0 in 2022, then tumbled by 48.73% to $342000.0 in 2023, then plummeted by 1665.5% to -$5.4 million in 2024, then rose by 1.4% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Cash from Financing Activities are -$5.3 million (Q4 2025), -$13000.0 (Q3 2025), and $179000.0 (Q2 2025).